(Gaithersburg, MD) – August 25, 2020 – Smithers, a leading provider of testing, consulting, information, and compliance services, announces the addition of state-of-the-art technologies to support any gene- and cell-based therapeutic development programs. Smithers is adding several key capabilities to its existing GLP/GCP, CLIA-certified, flow cytometry, ligand-binding, and cell-based assay services including qPCR, ddPCR, ELISPOT and hybridization ELISA to provide comprehensive bioanalytical support for gene- and cell-based therapeutics.
Smithers will be able to support PK and transcriptional biomarker studies by qPCR and ddPCR as well as functional cytokine production assays via ELISPOT in late 2020. This service complements Smithers capabilities and experience supporting immunogenicity studies including NAB and cell phenotyping for cell- and gene-therapy therapeutics.
“Cell- and gene-therapy are emerging as important classes of therapeutics for indications ranging from infectious disease to immuno-oncology. The market for cell- and gene-therapeutics is expected to continue to rise indicating that these technologies will become an increasingly important part of the bioanalytical market,” states Dr. Ira DuBey, President of Smithers Pharmaceutical Development Services division. “Smithers is proud to add these services to our portfolio. They enable us to continue to provide bioanalytical support for companies focused on cell- and gene- therapy.”
The Smithers Pharmaceutical Development Services division is a specialized, bioanalytical contract research organization (CRO) which provides a comprehensive range of services from discovery through phase IV for the development of large-molecule therapeutics. Smithers has two labs in the United States, located in Gaithersburg, Maryland and Ewing, New Jersey, with industry leading bioanalytical capabilities to support pharmaceutical development.
Smithers is committed to delivering accurate data, on time, with high touch and does so by investing in talent, technology, and quality assurance to better serve its clients and grow its market share in the life sciences industries, which include pharmaceutical, biotechnology, medical device, and environmental sciences.
Founded in 1925 and headquartered in Akron, Ohio, Smithers is a multinational provider of testing, consulting, information, and compliance services. With laboratories and operations in North America, Europe, and Asia, Smithers supports customers in the transportation, life science, packaging, materials, components, consumer, and energy industries. Smithers delivers accurate data, on time, with high touch, by integrating science, technology, and business expertise, so customers can innovate with confidence.